Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Cytosorbents (HQE) Stock Price & Analysis

0 Followers

HQE Stock Chart & Stats

€5.40€0.00(0.00%)
At close: 5:30 PM GMT+1
€9.5€9.75€10Mar 25Apr 8May 28
Day’s Range
EUR 5.40 - EUR 5.40
52-Week Range
EUR 4.16 - EUR 13.88
Previous Close
EUR 5.40
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 11.55M
Enterprise Value
EUR 49.06M
Total Cash (Recent Filing)
EUR 4.41M
Total Debt (Recent Filing)
EUR 26.33M
Price to Earnings (P/E)
―
Beta
0.76
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-0.8
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High Gross Margin

Gross margin above 70% provides meaningful contribution from each cartridge sold and creates potential operating leverage as revenue expands. Manufacturing optimization, sourcing improvements, and production efficiencies also support margin durability by strengthening the economics of the core consumables business.

Expanding Commercial Reach

Growth across distributor, partner, and direct-sales channels indicates broader commercial reach for CytoSorb rather than dependence on a single route to market. Expansion across territories can support repeat consumable demand and improve the company’s ability to convert hospital adoption into recurring sales.

Pipeline Optionality

HemoDefend-BGA adds a potential second platform beyond the current CytoSorb franchise, with validation and substantial non-dilutive funding already cited. Its development could create additional strategic or partnership value and diversify future growth opportunities if commercialization progresses.

Bears Say

Persistent Losses

Large ongoing losses and negative operating cash flow show that the current revenue base does not yet support the company’s cost structure. Until breakeven is achieved, internal funding for growth remains constrained and management’s improvement targets remain important to the business’s financial durability.

Weak Balance Sheet

Negative equity combined with substantial debt reduces financial flexibility and leaves less capacity to absorb operating setbacks. Persistent losses have eroded the capital base, increasing reliance on improved performance, external financing, or partnerships to support ongoing operations and strategic investment.

FDA And Clinical Uncertainty

The missed primary endpoint weakens the clinical foundation for DrugSorb-ATR, while the prior FDA denial means additional mechanistic data and real-world evidence are required. Regulatory uncertainty may delay U.S. commercialization and prolong investment before the opportunity can generate revenue.

Cytosorbents News

HQE FAQ

What was Cytosorbents’s price range in the past 12 months?
Cytosorbents lowest stock price was €4.16 and its highest was €13.88 in the past 12 months.
What is Cytosorbents’s market cap?
Cytosorbents’s market cap is €11.55M.
When is Cytosorbents’s upcoming earnings report date?
Cytosorbents’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is in 7 days.
How were Cytosorbents’s earnings last quarter?
Cytosorbents released its earnings results on Aug 06, 2026. The company reported -€1.245 earnings per share for the quarter, missing the consensus estimate of -€0.801 by -€0.445.
Is Cytosorbents overvalued?
According to Wall Street analysts Cytosorbents’s price is currently Undervalued.
Does Cytosorbents pay dividends?
Cytosorbents does not currently pay dividends.
What is Cytosorbents’s EPS estimate?
Cytosorbents’s EPS estimate is -0.80.
How many shares outstanding does Cytosorbents have?
Cytosorbents has 3,151,101 shares outstanding.
What happened to Cytosorbents’s price movement after its last earnings report?
Cytosorbents reported an EPS of -€1.245 in its last earnings report, missing expectations of -€0.801. Following the earnings report the stock price went up 3.289%.
Which hedge fund is a major shareholder of Cytosorbents?
Currently, no hedge funds are holding shares in DE:HQE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology